A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8. The objectives of this study are to determine the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).
Epistemonikos ID: 0b8e17e0b1cf02f324c550246f525bc52821d648
First added on: May 21, 2024